ArticleCureus2025
Pregnancy-Induced Atypical Hemolytic Uremic Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy that causes anemia, thrombocytopenia, and acute renal failure. In aHUS, a triggering event can lead to dysregulation of the complement immune system, leading to a cascade of events resulting in clot formation, capillary thrombosis, and renal dysfunction. Numerous triggers for aHUS exist, and pregnancy-associated aHUS (P-aHUS), in particular, is associated with poor maternal outcomes, with high risk for adverse events due to the inherent difficulties in establishing the diagnosis and treatment, along with the sequelae associated with the disease itself. We present a case of P-aHUS here, highlighting the diagnostic challenges, clinical management, and the importance of timely intervention, while also emphasizing the role of the monoclonal antibody drug eculizumab in its treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.